Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
Fmoc-AAGIGILTV-OH
3D-Ansicht

Biosynth logo

Fmoc-AAGIGILTV-OH

Ref. 3D-PP47642

Unbestimmte GrößeNachfragen
Voraussichtliche Lieferung in Vereinigte Staaten, am Donnerstag 12. Dezember 2024

Produktinformation

Name:
Fmoc-AAGIGILTV-OH
Beschreibung:

Peptide Fmoc-AAGIGILTV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Fmoc-AAGIGILTV-OH include the following: Rational design of peptide-based tumor vaccines WS Meng , LH Butterfield - Pharmaceutical research, 2002 - Springerhttps://link.springer.com/article/10.1023/A:1016497818471 Induction of melanoma-reactive CTL in HLA-A* 0201/K b transgenic mice by vaccination with peptides derived from MAGE-2 and MART-1 RPM Sutmuller, SH van der Burg , MJW Visseren - Immunology , 1997 - infona.plhttps://www.infona.pl/resource/bwmeta1.element.elsevier-b8764d78-8174-3548-9e3e-5a5b831cf1f6 Fluorescence labeling of anchor-modified Mart-1 peptide for increasing its affinity for HLA-A* 0201: Hit two targets with one arrow P Fattahi, N Salehi , Z Azizi - Journal of Peptide , 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.3480 Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes MJ Maeurer , HW Chan, J Karbach - European journal of , 1996 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830261112 Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue MJ Maeurer , A Necker, RD Salter - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.1580 Terminal modifications inhibit proteolytic degradation of an immunogenic mart-127-35 peptide: Implications for peptide vaccines LH Brinckerhoff, VV Kalashnikov - journal of cancer, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19991029)83:3%3C326::AID-IJC7%3E3.0.CO;2-X Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A JN Cormier, ML Salgaller, T Prevette - The cancer journal , 1997 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597550/ Mass-spectrometric evaluation of HLA-A* 0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100 JCA Skipper, PH Gulden - journal of cancer, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19990827)82:5%3C669::AID-IJC9%3E3.0.CO;2-%23 Detection of antigen-specific T-cells with MHC/peptide-tetramer-complexes G Tully, E Jager, MJ Maeurer - Clinical and Applied Immunology Reviews, 2002 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1529104902000569 MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A* 0201-restricted, Melan-A-derived peptide after active intracellular processing G Held, A Wadle, N Dauth - European journal of , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.200636545 TCR-induced alteration of primary MHC peptide anchor residue F Madura, PJ Rizkallah , M Legut - European journal of , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.201948085 Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading E Ranieri , LS Kierstead, H Zarour - Immunological , 2000 - Taylor & Francishttps://www.tandfonline.com/doi/pdf/10.3109/08820130009062294 Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type E Jaeger, R Salter, C Castelli, H Höhn - The Journal of , 2002 - journals.aai.orghttps://journals.aai.org/jimmunol/article/168/6/2766/34711 Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8 T cells using HLA-A2 E Jager, R Salter, C Castelli, H Höhn, K Freitag - J. Immunol, 2002 - academia.eduhttps://www.academia.edu/download/47681918/Impact_of_antigen_presentation_on_TCR_mo20160731-32057-yvft53.pdf Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A E Jager, H Höhn, J Karbach, F Momburg - journal of cancer, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19990611)81:6%3C979::AID-IJC22%3E3.0.CO;2-Y Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1 E Jager, H Höhn, A Necker, R Förster - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.10165 Diversity of the fine specificity displayed by HLA-A* 0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide D Valmori, N Gervois, D Rimoldi - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/161/12/6956/1064 Structural and functional characterization of peptide-beta2m fused HLA-A2/MART127-35 complexes C Shen, CC Chang, J Zhang, W Guo, L Xia - Biochemical and , 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006291X06001999 Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes C Pinilla , V Rubio-Godoy, V Dutoit , P Guillaume - Cancer Research, 2001 - AACRhttps://aacrjournals.org/cancerres/article-abstract/61/13/5153/507515 Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells C Douat-Casassus, N Marchand-Geneste - Journal of medicinal , 2007 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm0613368 Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A* 0201-binding peptides from the Melan-A/MART A van Elsas , SH van der Burg - European journal of , 1996 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830260803 Allogeneic Cell Therapy with Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Malignant Melanoma A Nolte, J Slotty, C Beike, WE Berdel - in Hematology and , 2003 - Springerhttps://link.springer.com/chapter/10.1007/978-3-642-55774-3_5 Stability and CTL activity of N-terminal glutamic acid containing peptides A Beck , MC Bussat, C Klinguer-Hamour - Journal of Peptide , 2001 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-3011.2001.00895.x Peptide-based strategies for targeted tumor treatment and imaging A Ayo, P Laakkonen - Pharmaceutics, 2021 - mdpi.comhttps://www.mdpi.com/1999-4923/13/4/481

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP47642 Fmoc-AAGIGILTV-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.